Incyte (Incyte) Price-to-Operating-Cash-Flow

: 23.84 (As of Today)

View and export this data going back to 1993. Start your Free Trial

As of today (2024-04-19), Incyte's share price is $52.35. Incyte's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.20. Hence, Incyte's Price-to-Operating-Cash-Flow Ratio for today is 23.84.

The historical rank and industry rank for Incyte's Price-to-Operating-Cash-Flow or its related term are showing as below:

INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 16.22 Med: 52.27 Max: 972.5
Current: 23.83

During the past 13 years, Incyte's highest Price-to-Operating-Cash-Flow Ratio was 972.50. The lowest was 16.22. And the median was 52.27.

INCY's Price-to-Operating-Cash-Flow is ranked better than
51.59% of 283 companies
in the Biotechnology industry
Industry Median: 24.39 vs INCY: 23.83

Incyte's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.65. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.20.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Incyte was -49.20% per year.

During the past 13 years, Incyte's highest 3-Year average Operating Cash Flow per Share Growth Rate was 193.70% per year. The lowest was -142.70% per year. And the median was 6.30% per year.

Incyte Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Incyte's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

26.74

21.75

18.55

28.57

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																18.55	24.97	17.92	20.60	28.57

Competitive Comparison

For the Biotechnology subindustry, Incyte's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Incyte's Price-to-Operating-Cash-Flow falls into.

Incyte Price-to-Operating-Cash-Flow Calculation

Incyte's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	52.35	/	2.196
	=	23.84

Incyte's Share Price of today is $52.35.
Incyte's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.20.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Incyte Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Incyte's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (Incyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

1INCY:Italy ICY:Germany ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Steven H Stein	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Vijay K Iyengar	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Thomas Tray	officer: Principal Accounting Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Sheila A. Denton	officer: EVP & General Counsel	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Edmund Harrigan	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Paula J Swain	other: Exec VP, Human Resources	C/O INCYTE CORPORATION, 3160 PORTER DRIVE, PALO LATO CA 94304
Pablo J Cagnoni	officer: President, R&D	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Maria E Pasquale	officer: EVP & General Counsel	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Dashyant Dhanak	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Barry P Flannelly	officer: See Remarks	ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Jonathan Elliott Dickinson	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Wendy L Dixon	director